DRG Market Assessment reports

The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and the long treatment duration. The availability of premium-priced branded agents prescribed…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key myasthenia gravis patient populations, covering 171 countries and…

Retinal vein occlusion (RVO) is a major cause of blindness in the major pharmaceutical markets. Patients are segmented by the anatomic location of the occlusion; thus, they are classified as having…

Clarivate Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…

Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States,…

In 2021, sales of branded biologics in ophthalmology totaled more than $9 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2021-2031 forecast period, the…

In 2021, sales of branded biologics in immunology exceeded $70 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…

In 2021, sales of branded biologics for respiratory indications totaled about $0.7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2021-2031…

In 2021, sales of branded MAb biologics in oncology exceeded $36 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5…

In 2021, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled more than $2.5 billion in the major pharmaceutical markets under study (…

Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…

In 2021, sales of insulins at the ex-manufacturer price level exceeded $20 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2021-2031 forecast…